

Andrew Cheng, M.D., Ph.D.

Year of birth 1967
Nationality US-American
Place of residence Burlingame, CA, USA
Initial appointment -



Professional development

Akero Therapeutics, Inc., South San Francisco, CA

2018-present President and Chief Executive Officer

Raised approx. US\$ 375 million in funding (US\$ 47 million Crossover, US\$ 109 million IPO and US\$ 217 million Follow on). Recruited five new independent members for the board of directors. Advanced lead asset, efruxifermin (FGF-21-Fc fusion protein) from IND to Phase 2B. Grew company from two employees to 35.

Gilead Sciences, Foster City, CA

2018 Chief Medical Officer, Executive Vice President
2015-2018 Executive Vice President, Clinical Research and Development Operations
2009-2015 Senior Vice President, Clinical Research and Development Operations
2005-2009 Vice President, Clinical Research
2004-2005 Senior Director, Clinical Research
2002-2004 Director, Clinical Research
1999-2002 Associate Director, Clinical Research

Over 19 years, Andrew Cheng was involved in major roles in New Drug Applications (NDAs) and Marketing Authorization Applications (MAAs) of 11 new molecular entities. He was leading the therapeutic area for HIV and CV with oversight for global medical affairs. He created the Development Operations department (Regulatory, Clinical Operations, Biometrics, Pharmacovigilance, Clinical Pharmacology and Project Management Depts) at Gilead and supported all clinical research (HIV, CV, Liver Disease, Immunology, Oncology and Respiratory).

Education

1996 M.D. Columbia University, College of Physicians and Surgeons, Medical Scientist Training Program (M.D.-Ph.D. Program), NY, NY
1995 Ph.D. Columbia University, College of Physicians and Surgeons, Integrated Program Genetics and Biochemistry, NY, NY
1988 B.A. Honors Johns Hopkins University, Baltimore, MD (Biology)

As of March 2022

Postdoctoral Training

Internship and Residency

1997-1999	Resident in Medicine, UCLA Hospital, Los Angeles, CA
1996-1997	Intern in Medicine, California Pacific Medical Center, San Francisco, CA

Licensure and Certification

1999	Diplomate, American Board of Internal Medicine
1997	California Medical License
1997	Drug Enforcement Agency

Memberships (i) in statutory supervisory boards and/or (ii) in comparable domestic or foreign supervisory bodies of commercial enterprises

- (i) None

- (ii) 2017-present Vera Therapeutics, Inc., Brisbane, California, USA (listed), Member of the Board of Directors

2019-Mai 2022 Arbutus Biopharma Corporation, Warminster, Pennsylvania, USA (listed), Member of the Board of Directors (Mr. Cheng will leave the Board of Directors of Arbutus Biopharma Corporation on May 25, 2022.)

The proposed candidate does not have any personal or business relationship with MorphoSys AG or its group companies or the corporate bodies of MorphoSys AG, which would have to be disclosed pursuant to the German Corporate Governance Code. A disclosable personal or business relationship with a shareholder with a material interest in MorphoSys AG as defined by the German Corporate Governance Code does not come into consideration, as MorphoSys AG has no such shareholder. Furthermore, all members of the Supervisory Board of MorphoSys AG are independent per definition of the German Corporate Governance Code.